Nanotechnology Now







Heifer International

Wikipedia Affiliate Button


DHgate

Home > Press > Celator(R) Pharmaceuticals Announces Positive Data From Phase 2 Study of CPX-351 in Acute Myeloid Leukemia

Abstract:
Celator Pharmaceuticals, Inc. today announced positive results from its Phase 2 study of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection versus conventional cytarabine and daunorubicin (the "7+3" regimen) in patients, 60-75 years of age, with untreated acute myeloid leukemia (AML).

Celator(R) Pharmaceuticals Announces Positive Data From Phase 2 Study of CPX-351 in Acute Myeloid Leukemia

Princeton, NJ | Posted on May 3rd, 2010

The primary endpoint of the study, the rate of patients achieving a complete remission with CPX-351 compared to "7+3," achieved statistical significance. In addition, there was a reduction in the 30-day and 60-day mortality with CPX-351 versus the "7+3" regimen.

The multicenter, randomized, open-label trial enrolled a total of 126 patients between November 2008 and October 2009. Patient follow-up is ongoing. Results from this study will be submitted to a major medical conference in 2010.

"The control arm, cytarabine plus daunorubicin, has been the standard of care for treating patients with AML for more than 30 years," said Arthur Louie, MD, chief medical officer at Celator Pharmaceuticals, Inc. "To demonstrate an improvement in complete remission rate coupled with an improvement in early death rate is very encouraging. We expect to have additional information on the secondary endpoints later this year."

The primary endpoint of the study was a comparison of complete remission rates - which includes complete remissions (CR) and complete remissions with an incomplete recovery, to a specified level, of neutrophils and/or platelets (CRi). Both CR and CRi result in patients becoming leukemia-free. The secondary endpoints of the study include duration of complete remission, event-free survival, 12-month survival, and the rate of patients going on to receive stem cell transplantation. The full safety analysis will include 30-, 60-, and 90-day mortality rates.

"We are very excited that CPX-351 may offer patients a new, more effective treatment option," said Scott Jackson, chief executive officer at Celator Pharmaceuticals, Inc. "These data suggest that our approach with CPX-351 significantly improves clinical benefit compared to conventional administration of cytarabine and daunorubicin. We will meet with the FDA later this year to discuss our results and plans for a Phase 3 study of CPX-351 in AML."

####

About Celator Pharmaceuticals
Celator Pharmaceuticals, Inc., with locations in Princeton, NJ, and Vancouver, BC, is a privately held pharmaceutical company developing new and more effective therapies to treat cancer. CombiPlex®, the company's proprietary drug ratio technology platform, represents a novel approach that identifies molar ratios of drugs that will deliver a synergistic benefit, and locks the desired ratio in a nano-scale drug delivery vehicle that maintains the ratio in patients with the goal of improving clinical outcomes. The company pipeline includes two phase 2 products; CPX-351 (a liposomal formulation of cytarabine:daunorubicin) for the treatment of acute myeloid leukemia and CPX-1 (a liposomal formulation of irinotecan:floxuridine) for the treatment of colorectal cancer; a preclinical stage compound, CPX-571 (a liposomal formulation of irinotecan:cisplatin); and multiple research programs, including the hydrophobic docetaxel prodrug nanoparticle (HDPN) formulation being studied by the National Cancer Institute's Nanotechnology Characterization Laboratory. Based on the applications of CombiPlex and the proprietary nanoparticle prodrug delivery platform, Celator is positioned to advance a broad pipeline of cancer therapies involving both previously approved and novel drug agents. For more information, please visit the company's website at www.celatorpharma.com. Information on ongoing trials is available at www.clinicaltrials.gov.

About CPX-351
CPX-351 (Cytarabine:Daunorubicin) Liposome Injection represents a new approach to developing combinations of drugs in which drug molar ratios with synergistic anti-tumor activity are encapsulated in a drug delivery vehicle in order to maintain the desired ratio following administration. CPX-351 has been granted orphan drug status by the U.S. Food & Drug Administration (FDA) for the treatment of AML. Celator is currently conducting a second randomized phase 2 study of CPX-351 versus intensive salvage therapy in patients up to 65 years of age with AML in first relapse. Enrollment is expected to be completed in 2010. This study is supported by The Leukemia & Lymphoma Society.

For more information, please click here

Contacts:
Celator Pharmaceuticals, Inc.
303B College Road East
Princeton, NJ 08540
USA
Telephone: (609) 243-0123
Fax: (609) 243-0202

Copyright © Celator Pharmaceuticals

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Toyocolor to Launch New Carbon Nanotube Materials at nano tech 2015 January 24th, 2015

NANOPOSTER 2015 - 5th Virtual Nanotechnology Conference - call for abstracts January 24th, 2015

Nanosensor Used for Simultaneous Determination of Effective Tea Components January 24th, 2015

The latest fashion: Graphene edges can be tailor-made: Rice University theory shows it should be possible to tune material's properties January 24th, 2015

Possible Futures

Nanotechnology in Energy Applications Market Research Report 2014-2018: Radiant Insights, Inc January 15th, 2015

'Mind the gap' between atomically thin materials December 23rd, 2014

A novel method for identifying the body’s ‘noisiest’ networks November 19th, 2014

Researchers discern the shapes of high-order Brownian motions November 17th, 2014

Nanomedicine

Teijin to Participate in Nano Tech 2015 January 22nd, 2015

2nd International Conference on Infectious Diseases & Nanomedicine (December 15-18, 2015, Kathmandu, NEPAL) January 22nd, 2015

Anti-microbial coatings with a long-term effect for surfaces – presentation at nano tech 2015 in Japan January 21st, 2015

A spoonful of sugar in silver nanoparticles to regulate their toxicity January 21st, 2015

Announcements

Toyocolor to Launch New Carbon Nanotube Materials at nano tech 2015 January 24th, 2015

NANOPOSTER 2015 - 5th Virtual Nanotechnology Conference - call for abstracts January 24th, 2015

Nanosensor Used for Simultaneous Determination of Effective Tea Components January 24th, 2015

The latest fashion: Graphene edges can be tailor-made: Rice University theory shows it should be possible to tune material's properties January 24th, 2015

Nanobiotechnology

DNA 'glue' could someday be used to build tissues, organs January 14th, 2015

Photonic crystal nanolaser biosensor simplifies DNA detection: New device offers a simpler and potentially less expensive way to detect DNA and other biomolecules through changes in surface charge density or solution pH January 13th, 2015

Determination of Critical Force, Time for Manipulation of Biological Nanoparticles January 7th, 2015

DNA Origami Could Lead to Nano “Transformers” for Biomedical Applications: Tiny hinges and pistons hint at possible complexity of future nano-robots January 5th, 2015

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More










ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2015 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE